KIF18B: A Potential Drug Target for Energy Metabolism and Disease

Target Name: KIF18B

NCBI ID: G146909

KIF18B

KIF18B: A Potential Drug Target for Energy Metabolism and Disease

Kinesin family member 18B (KIF18B) is a protein that plays a critical role in the structure and function of the mitochondria, which are essential for energy metabolism in all living organisms. KIF18B is a member of the kinesin family, which is known for their ability to transport proteins across the mitochondrial inner membrane during protein import and export.

Recent studies have identified KIF18B as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The reason for its potential as a drug target is its unique structure and function, as well as its involvement in several cellular processes that are associated with the development and progression of these diseases.

One of the key functions of KIF18B is its role in the regulation of mitochondrial protein import and export. This is critical for maintaining the proper structure and function of the mitochondria, which are responsible for generating the majority of the energy for the cell. Imbalances in protein import and export can lead to the accumulation of damaged or dysfunctional proteins in the mitochondria, which can contribute to the development of various diseases.

In addition to its role in protein import and export, KIF18B is also involved in the regulation of mitochondrial fusion and fusion-based processes. This is important for maintaining the integrity of the mitochondrial membrane, as fusion events can lead to the formation of toxic mitochondrial stress granules that can damage the cell and contribute to the development of certain diseases.

KIF18B is also involved in the regulation of cellular signaling pathways that are important for cell growth, apoptosis, and metabolism. Its role in these processes makes it an attractive target for drugs that are aimed at preventing or treating various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

Another potential mechanism by which KIF18B may be targeted as a drug is its role in the regulation of inflammation. Chronic inflammation is associated with the development and progression of many diseases, including cancer, and KIF18B is involved in the regulation of the production and response to inflammation. This makes it a potential target for drugs that are aimed at reducing inflammation and preventing the development of these diseases.

In conclusion, KIF18B is a protein that plays a critical role in the structure and function of the mitochondria, and its potential as a drug target is due to its unique structure and function, as well as its involvement in several cellular processes that are associated with the development and progression of many diseases. As research continues to unravel the mechanisms by which KIF18B functions, it will be exciting to see if drugs can be developed that target this protein and prevent or treat a variety of diseases.

Protein Name: Kinesin Family Member 18B

Functions: In complex with KIF2C, constitutes the major microtubule plus-end depolymerizing activity in mitotic cells. Its major role may be to transport KIF2C and/or MAPRE1 along microtubules

The "KIF18B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF18B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets